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in Cell Culture-Based Influenza Vaccine Production
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Bioprocess Engineering at MPI
Fundamental research on cell culture 
based Influenza vaccine production:
• Process optimization 
(esp.: cell growth and virus yield)
• Mathematical modeling
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Needed:
Understanding of production 
systems and parameters 
on molecular level
(e.g.: virus  host cell interaction)
hemagglutinin nucleocapsid:(s/s (-) sense RNA;
polymerase: PB1, PB2, 
PA; nucleoprotein
lipid envelope
neuraminidase
Influenza Virus 
Hemagglutinin Trimer
Max Planck Institute Magdeburg Omics in Cell Culture-Based Influenza Vaccine Production 3May 24th, 2012
M1 (matrix protein) 
M2 (ion channel) Ø 70-120 nm
virus type geographic origin strain number year of isolation
virus subtypehost
human Influenza A Puerto Rico 8/34 H1N1
Edited from PDB: 1RU7F: molecule 1RU7, chain 70;
Gamblin et al., Science, 2004, Vol 303, p. 1838-1842 
3-9 N-Glycosylation Sites
Our Motivation for Digging into Glycosylation 
Change of common influenza vaccine production process
in chicken eggs to production in mammalian cell cultures
Influenza vaccine production process 
(understanding & optimization)
One important aspect: 
N-glycosylation pattern of the major viral membrane-
glycoproteins Hemagglutinin (HA) and Neuraminidase (NA)
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Ribbon representation of the HA0 trimer 
from the 1918 influenza A virus
Source: http://www.accessexcellence.org/WN/SU/avianflufeb04.htm 20.10.05
Glycosylation pattern may affect:
- Viral immunogenicity
- Virus attachment to host cells
- Viral replication dynamics
Glycosylation pattern of may be affected by:
- USP: Virus strain, host cell type, cultivation conditions, 
virus inactivation
- DSP: Each step of: filtration, centrifugation, 
& chromatography 
and the type of adjuvanting
Glycoconjugates / Glycosylation
Glycoconjugates
N-Glycosylation
O-Glycosylation Glycolipids
• Glycan attached to nitrogen 
atom of the amino acid asparagine
• Glycan attached to oxygen 
atom of the amino acids 
serin and threonine
• Glycan attached to ceramide 
(glycosphingolipids) or 
phosphatidylglycerol
(glycophospholipids)
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Typical N-Glycans of Mammalian Cells
High-Mannose Type Complex Type Hybrid Type
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Antennas Bisecting Core Fucose
Core
Mannose (Man)
Galactose (Gal)
Sialic Acid (SA)
Fucose (Fuc)
N-Acetylglucosamine (GlcNAc)
Impact of Complex Carbohydrates
• Key-and-Lock principle 
for receptors and ligands. 
• Signal transduction /
Oligosaccharides, glycolipids, glycans etc. play a central role 
in many aspects of life:
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communication between 
cells and pathogens.
• Modification of enzyme / protein
activities and specificities. 
• Potency and specificity of new drugs and vaccines. 
• Health-promoting / preventive functions in food, food additives 
and functional food.
xCGE-LIF for Glycoanalysis
Principles and Advantages
--
Time
--
Time
-
- --
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separation by m/z separation by 
molecular shape
• NO sample carryover   //   Only ion migration
• Extraordinary separation power and sensitivity
• High reproducibility of migration times ( Longterm RSD for < 0,5%)
• Good reproducibility of relative peak heights ( RSD < 5%)
• Fully automated multicapillary array systems enable “real” HT 
=>   xCGE-LIF with up to 96 capillaries
AND
First powerful "real" HT glycoanalysis-tool 
(method, software with GUI & database):
the  "glyXbox"
⇒ Sample preparation methods
⇒ Glycoanalysis with:
System (Method, Software & Database) 
for Automated HT Glycoanalysis via xCGE-LIF
(Ongoing project of M. Borowiak (glyXera), PhD thesis of R. Hennig & PhD thesis of T. Muth)
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• Automated parallel separation and sensitive
detection with xCGE-LIF systems
• Automated data-processing (glyXdata) 
• Automated data-analysis (glyXtool)
⇒ Glycodatabase:
an oligosaccharide / glycan database (glyXbase)
⇒ The system is ready for take-off !
www.glyxera.com
Protein Separation by 1D/2D-GE
& Cut out of Bands/Spots:
1c
Fluorescent Labeling of Released 
N-Glycans with APTS
3
Using glyXbox for 
Automated HT-Glycoanalysis via xCGE-LIF
Protein Precipitation
(e.g. to Extract Proteins from
Citrate Blood Plasma)
1a Protein Purification & Concentration
by Affinity-SPE 
(e.g.: Protein A Beads)
1b
Post Labeling Clean-Up4 On-Membrane,  In-solution or In-Gel, 
Deglycosylation (by PNGase F):
2
(Project of R. Hennig, T. Muth & M. Borowiak)
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APTS
Reducing
Agent
Acid
APTS
Capillary
DNA 
Sequencer
xCGE-LIF Analysis, 
Normalization & Data Evaluation
6Addition of 
Internal Standards
5
Sample Sample/StandardMix
+ Internal Standard
Schwarzer J, Rapp E, Reichl U, Electrophoresis 2008, 29, 4203-4214.
Ruhaak L, Hennig R, Huhn C, Borowiak M, Dolhain R, Deelder A, 
Rapp E, Wuhrer M, J Proteome Res 2010, 9, 6655-6664.
Rapp E, Schwarzer J, Reichl U, Bohne C: European patent: 
EP 08007887.6 (24.4.2008).
Rapp E, Schwarzer J, Reichl U, Bohne C: US patent: 
US 12/428,003 (22.4.2009).
- SEC
- HILIC-SPE
- NONE
PNGase F
glyXbox
(Ongoing project @ glyXera, PhD thesis of R. Hennig & PhD thesis of T. Muth)
Software-Development for
Automated HT Glycoanalysis via xCGE-LIF
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Growing Glycan / Oligosaccharide Library 
for Structural Elucidation via “Migration-Time-Matching”
Excerpt from 
in-house library:
(Ongoing project of R. Hennig & R. Kottler)
tmig in MTU‘‘
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At present:
• Over 70 entries for N-glycans.
• Normalized migration times for two different gel matrices.
• Human milk oligosaccharide database started (about 30 entries).
Summary I
• Systems allows fast and easy characterization of 
N-glycosylation patterns (qualitative & quantitative) 
and other carbohydrate pools.
• Highly sensitive - high resolution - “real” high throughput
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system & method for profiling glycoproteins 
and other carbohydrate mixtures.
• N-Glycans and other carbohydrates can be analyzed on three levels:
• Fingerprint Analysis
• Glycoprofiling  
• Extended Structural Analysis 
SDS-PAGE of Variants of Human Influenza Virus 
Type A (H1N1, H3N2) and Type B (B/Mal)
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Schwarzer J, Rapp E, Hennig R, Genzel Y, Reichl U, Vaccine 2009, 27, 4325–4336.
Higher molecular weights MW for all variants of the H3N2 virus, 
compared to the H1N1 variants. 
Differences in Molecular Weight of HA 
Due to Differences in N-Glycosylation
variant 
and
virus 
overall MW of HA
(estimated via SDS-PAGE)
[kDa]
calculated mass of
HA AA1sequence* 
[kDa]
Estimated mass of
HA N-glycan pool
[kDa]
TNP tmig range of 
HA N-glycans 
[bp]
M      H1N1 79±5 63.0 16±5 16 273.3-426.5
V      H1N1 68±5 63.0 5(±5) 16 214.0-378.3
C      H1N1 68±5 63.0 5(±5) 14 222.5-385.0
H      H1N1 68±5 63.0 5(±5) 14 243.0-406.9
A      H1N1 65±5 63.0 2(±5) 11 214.0-406.9
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M      H3N2 95±5 62.1 31±5 34 57.9-418.0
V      H3N2 81±5 62.1 17±5 29 51.8-372.5
R      H3N2 93±5 62.1 29±5 19 64.0-308.9
M      B/Mal 86±5 65.6 22±5 37 171.5-418.0
• Almost identical MW comparing only AA-sequences
• Significant differences in MW for glycosylated forms 
(virus & host cell related) 
Variations in the MW of the HA proteins of the different virus variants 
correlate with their HA N-glycan amount (TNP) and size distribution. 
Application of glyXbox to Generate 
HA N-Glycan Fingerprints of Influenza Viruses 
Produced in Different Cell Lines 
Variants of H1N1
M-variant400
0
200
0
400
0
350
0
300
V-variant
R
F
U
C-variant
A-variant
H-variant
Differences host cell related
Cell line: 
HepG2
(human) 
A549
(human) 
AGE.1CR
(duck) 
Vero
(monkey) 
MDCK
(dog) 
(PhD thesis of S. Schwarzer & J. Rödig – partly in coop. with ProBioGen (Berlin/D))
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20
Total No. of Peaks
(TNP)
0 10tmig in bp
0
52035
40
TNP
0 20
M-variant
tmig in bp
1150
0
500
0
300
0
35 520
V-variant
R
F
U
R-variant
Variants of H3N2
Cell line: 
RCAr
recomb.
MDCK 
(dog) 
Vero
(monkey) 
MDCK
(dog) 
Differences virus related
Structural Investigation of HA N-glycan Pools
of the Different Influenza Viruses
virus and variant complex type; 
with terminal …
core 
fucosylation
high mannose type hybrid type
A/PR/8/34 H1N1
M-variant all; α- (8; 10-16)2 and β-galactose 
(2-7; 9) 2
yes no no
V-variant most; β-galactose (6-16) 2 yes some no
C-variant most; β-galactose (5-14) 2 yes some some
A-variant all; β-galactose (5-11) 2 yes no no
H-variant all; β-galactose (4-14) 2 yes no no
=>   detailed structural information via SED and “in-house” database matching
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A/WSN/67/2005 H3N2
M-variant few; α- and β-galactose
(some > 16) 2
ND1 major peaks
(< 16, some >16) 2
no
V-variant some; β-galactose 
(17,18,23, some > 23) 2
ND1 major peaks
(9-16, 19-22, some > 23) 2
no
R-variant no ND1 few 
(11,14,15,17,19) 2
major peaks
(12,13,16,18) 2
B/Mal/2506/2004
M-variant some; β-galactose 
(13-15, some > 15) 2
ND1 major peaks 
(all < 13, some > 15) 2
no
1  ND, not determined 
2 numbers of the peaks (corresponding to glyXdata peaklists of the normalized EPGs) related to the particular N-glycan types
Summary II
• Virus and host cell type are determining the HA 
N-glycosylation pattern.
• Both seem to impact the principal N-glycan type attached.
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• Virus mainly determines the number of different N-glycans attached.
• Host cell mainly causes: - Variations of (monomeric) constitution 
of single N-glycans.
- Shifts of N-glycan pool composition.
(percentage of different N-glycan types)
Virus Adaptation to Host Cells
Sequence Analysis of Virus Genomes
Influenza Virus A PR/8/34 (H1N1) from RKI
Influenza Virus A PR/8/34 (H1N1) from NIBSC
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MDCK Vero MDCK
N-Glycosylation Pattern Analysis
1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th
Virus Titer Improves During Adaptation
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Host Cell Specificity of HA N-Glycosylation
(Changes during Adaptation)
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HA Quasispecies Composition
RKI  ↔ NIBSC
Influenza Virus A PR/8/34 (H1N1) from RKI
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Influenza Virus A PR/8/34 (H1N1) from NIBSC
Substitution Sites within the HA-Molecule
A/PR/8/34 
from RKI
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A/PR/8/34 
from NIBSC
Edited from PDB; molecule 1RU7
Edited from PDB; molecule 1RU7
Do Substitutions Increase 
Viral Fitness in Vero?
N-Glycosylation Pattern Analysis
Sequence Analysis of Virus Genomes
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MDCK Vero MDCK
1st 2nd 3rd 4th 5th 6th 7th 8th 9th 10th 11th
Vero
Improved 
viral 
Fitness ?
?
Improved Viral Fitness also in Vero !
MDCK Vero MDCK Vero
H1N1/PR/8/34/NIBSC
initial
Vero-experienced
NIBSC / RKI 2nd
12th
12th
13th/ 14th
13th/ 14th
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H1N1/PR/8/34/RKI
initial
Helene Kaffka
Initial Seed RKI
(2nd)
Initial Seed NIBSC
(2nd)
Vero-exp.1 RKI
(12th)
Vero-exp.2 RKI
(13th)
Vero-exp.3 RKI
(14th)
Vero-exp.2 NIBSC
(13th)
Vero-exp.3 NIBSC
(14th)
Vero-exp.1 NIBSC
(12th)
2nd
Summary III
• „Unexperienced“ Influenza viruses being adapted to new host cells 
need 2-3 passages to stabilize their glycosylation pattern.
• NIBSC derived seed virus shows much more heterogeneous 
quasispezies composition than RKI derived. 
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• Challenging Influenza viruses with new host cells results in “rescue 
mutations” and quasispezies diversification.
• “Experienced” Influenza viruses show improved viral fitness.
Impact of HA N-Glycosylation on Immunogenicity of 
Influenza Viruses Produced in Different Cell Lines 
Supernatant:
Cytokine production
(IL-2, IFN-γ, IL-4)Isolation of 
spleen cells
HA110-120 (synthetic peptide)
MDCK-variant (glycos./ deglycos.)
Vero-variant    (glycos./ deglycos.)
 Whole spleen cell stimulation assay (in vitro)
(PhD thesis of J. Rödig - in coop. with Dr. Bernd Lepenies @ MPI of Colloids and Interfaces)
Max Planck Institute Magdeburg
Incubation at 37 °C for 48 h  
Cells:
T cell activation markers
(CD69, CD25)
TCR-HA transgenic mouse
(TCRαβ specific for HA110-120)
(performed by Julia Hütter @ MPI of Colloids and Interfaces)
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HA N-Glycosylation Impacts T Cell Activation
Max Planck Institute Magdeburg
 Significantly higher frequency of T cells expressing the activation marker CD69 
upon stimulation with the Vero cell-derived influenza virus glycovariant
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HA N-Glycosylation 
Affects Cytokine Production
Max Planck Institute Magdeburg
 IL-2 and IFN-γ are produced in significantly higher levels by splenocytes 
stimulated with the Vero cell-derived influenza virus glycovariant
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Hemagglutinin - Derived from 
Glycosylated & Deglycosylated Virus
MDCK cell-
derived 
Influenza Virus 
A PR/8/34 (H1N1)
fully N-glycosylated
deglycosylated
overlay
(PhD thesis of J. Rödig - in coop. with Dr. Bernd Lepenies @ MPI of Colloids and Interfaces)
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Vero cell-
derived 
Influenza Virus 
A PR/8/34 (H1N1)
fully N-glycosylated
deglycosylated
overlay
Virus Deglycosylation Abolishes 
Cytokine Production
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Summary IV
 The platform of pyrosequencing, glycoanalysis and 
immunogenicity assays allows to investigate immunogenic 
differences of influenza virus glycovariants.
 Hemagglutinin N-glycosylation has a significant impact 
Max Planck Institute Magdeburg
on immunogenicity.
 The differential immune stimulatory effects mediated by the 
influenza virus glycovariants seem to be also relevant in vivo.
 These findings might impact cell line-based influenza vaccine 
design.
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Outlook 
• Screening for the optimal influenza production system
using pyrosequencing, glycoanalysis and immunogenicity assays
=> “Sweet” vaccine design
• Extension of N-glycan and HMOS libraries and generation of other 
oligosaccharide libraries  (e.g. O-glycans) 
• Applying this method to other fields: 
(e.g. in the context of the "HighGlycan" EU-consortium)
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- Glycome GWAS studies
- Biopharmaceuticals like recombinant glycoproteins or vaccines
- Functional food (e.g. infant nutrition) & food additives
- Large scale clinical studies
- Early diagnosis of diseases (e.g.: diabetes, cancer, …)
- ... 
• Commercialized via: www.glyxera.com
… the BPE-Group
esp.:
• Yvonne Genzel
Thanks  to ...
…   YOU ... our  cooperation partners:
Max Planck Institute Magdeburg
• Udo Reichl
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… and the A-Team !!!
esp.:
• Jana Schwarzer
... now J.Bohne
@ Novartis Vaccines
• Jana Rödig
• René Hennig
Influenza Vaccine Production
• 1-3 eggs per vaccination
• 5 mio. vaccinations every year
Classical production: Trend:
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Advantages:
• Cell culture derived viruses are closer to the lateron human host   
• Alternative for patients showing allergic reactions against chicken proteins
• Enables faster vaccine production scale-up in case of epidemics or pandemics
• Enables vaccine production for protection against avian influenza (H5N1)
Chicken eggs Mammalian cell culture
Labeling
N-Glycan
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Modified from: Chen et al. (1998) Glycobiology (8): 1045-1052
APTS = 8-amino-l,3,6-pyrenetrisulfonic acid
APTSAPTS+ NaBH3CN
Acid
Schematic Representation of N-Glycans
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Sequential Exoglycosidase Digestion
NeuAcα(2-3/6)Galβ(1-4)GlcNAcβ(1-2)Manα(1-6)
NeuAcα(2-3/6)Galβ(1-4)GlcNAcβ(1-2)Manα(1-3)
Manβ(1-4)GlcNAcβ(1-4)GlcNAc
Fucα(1-6)
α-Fucosidase
*
*
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0
10000
20000
30000
40000
0 2000 4000 6000
1 RFU
1
2
time (min) 
α-sialidase
β-galactosidase
β-N-acetylhexosaminidase
α-mannosidase
* can be substituted with α-galactose
Back1 Back2
Bio/Process-Analytics
Hardware-, Software-
& 
Method-Development
Genomics
Qualitative 
Protein Analysis
Quantitative 
Protein Analysis
Analysis of Post-
Translational Modifications
• Phosphorylation
• Glycosylation
• …
Transcriptomics
Proteomics Metabolomics
Team: 9 PhD Students, 8 Students, 1 Techn. Assistant
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• Glycans
• Glycopeptides
• Glycoproteins
and
• other Carbohydrates
(e.g.: Milk oligosaccharides) 
Glycomics,
Glycoproteomics
& 
Carbohydrate 
Analytics
• Capillary-(Gel-)Electrophoresis Systems:
- CE System with UV-Detection
- Multiplexing CGE-LIF Systems (xCGE-LIF)
• HPLC Systems: - HPLC-FLR
- nanoHPLC-LIF
- HPAEC-PAD
• Diverse Gelelectrophoresis Systems
(1D, 2D & DIGE) 
• LC-MS/MS Systems: 
- Online: nanoHPLC-QqTof & nanoHPLC-QIT 
- Offline: 2D-nanoHPLC & MALDI-Tof/Tof
• GC-MS/MS System
Instrumentation:
Glycomics & Glycoproteomics
Toolbox
Glycan Analysis
Glycopeptide analysis
In-gel-geglycosylation
with endoglycosidase
Glycans
Glycopeptide trapping and 
separation by (2D)-nano-HPLC
proteolytic digestion
non labelled
Glycan trapping and 
separation
by (2D)-nano-HPLC
directly spotted onto 
pos. labelled
neg.  Labelled
2AB/AA-glycans
HPLC 
APTS-glycans
CGE 
Protein Analysis
GLYCOMICS
GLYCOPROTEOMICS
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Separated glycopeptides 
directly spotted onto 
MALDI targets  via micro-
fraction-collector
Online detection by 
ESI-(MS/)MS
Optional on 
target deglycos.
with endo-
glycosidase
Identification of glycosylation sites
Consecutive eluting
glycopeptides
MALDI targets 
Offline detection by
MALDI-MS(/MS)
Structural elucidation of glycans
Database 
Search
Database 
Search
Offline detection by
MALDI or nanoESI-
MS(/MS)
Offline detection by
MALDI-MS(/MS)
glycan
fingerprint
Seq. Exoglyco-
sidase Digest.
HPLC
glycan
fingerprint
glycan
fingerprint
Seq. Exoglyco-
sidase Digest.
CGE
glycan
fingerprint
Online detection by 
ESI-(MS/)MS
CGE-LIF Based Glycomics
Glyco-
proteins
In-gel  /  In-solution
Deglycosylation
with Endoglycosidase
Glycans Fluorescent Labelling
with  APTS 
APTS-Glycans
Protein 
Analysis
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Structural elucidation Database Search
CGE-LIF 
Analysis
Sequencial 
Exoglycosidase 
Digestion (SED)
CGE-LIF 
Analysis
"Fingerprint" 
Comparison
Electropherogram
Overlay
HILIC-FLR vs. xCGE-LIF
Separation power, performance and sensitivity:
xCGE-LIF (via DNA-Sequencer)
(sample amount 2 nL)
HILIC-FLR
(sample amount 7500 nL)
Max Planck Institute Magdeburg Omics in Cell Culture-Based Influenza Vaccine Production 42May 24th, 2012
Separation of two aliquots of the same sample:   the "blood-plasma glycome"
⇒ Separation power more than one order of magnitude better !
⇒ Sensitivity more than three orders of magnitude higher ! 
xCGE-LIF Analysis of N-Glycan Pools
(Normalized Electropherogram = “ Fingerprint”)
• Limit of detection:
50 attomole on column. 
• Linear dynamic range:
Overlay of 12 "fingerprints" of the N-glycan pool of a mAB:
(LOD and reproducibility of xCGE-LIF)
I
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U
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4 orders of magnitude. 
• Good reproducibility
with respect to 
relative peak heights.
• RSD for migration times of more than 36 consecutive runs < 0,03%. 
(xCGE-LIF analyses of 3 techn. replicates à 12 repeated runs)
• Longterm RSD (about two years) for migration times < 0,5%.
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(Project of R. Hennig & M. Borowiak - in coop. with Dr. Manfred Wuhrer @ LUMC (Leiden/NL))
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⇒ Separation of more than 4500 samples in 48 hours !
⇒ Due to multiplexing with up to 96 capillaries in parallel, 
90 - 450 times faster than comparable analysis methods !
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Separation Power of N-Glycan Analysis 
via xCGE-LIF
A2FG2S2(2,6)
i
n
 
R
F
U
 
 
(
O
f
f
s
e
t
 
2
0
0
0
 
R
F
U
)
Max Planck Institute Magdeburg Omics in Cell Culture-Based Influenza Vaccine Production 45May 24th, 2012
A2FG2S1(2,3)
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A2FG2S1(2,3)
cell line derivation application
CHO Chinese hamster ovary good product glycosylation
CHO dhfr Mutant for genetic amplification recombinant products
BHK21 Syrian hamster viruses/veterinary vaccines
HeLa Human cervical adenocarcinoma polio vaccine
Namalwa Human B lymphoblastoid Interferon
Typical Cells
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COS 1/COS 7 African green monkey kidney recombinant products
293 Adenovirus transformed HEK Gene therapy
Sf9 Spodoptera frugipeda Baculoviruses
MDCK Cocker spaniel kidney viral vaccines
Vero African green monkey, kidney viral vaccines
AGE1.CR Duck, retina viral vaccines
A549 Human, lung epithel carcinoma viral vaccines
HepG2 Human, hepatocell. epith. carcin. viral vaccines
RCAr modified MDCK viral vaccines
Antigenic Drift
RNA
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Hemagglutinin
Neuraminidase
Antibodies
Sialic acid
Modified from: Influenza: Virus and Disease; Roche homepage; Oktober 2005
modified antigen
back
Antigenic Shift
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Reassortment
Modified from: Influenza: Virus and Disease; Roche homepage; Oktober 2005back
HA N-Glycan Fingerprints of Different Human 
Influenza Viruses Produced in MDCK cells
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Differences virus related
Quasispecies Composition - RKI
Multiple Substitutions in Consensus Sequence
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=> Substitutions Improve Viral Fitness in Vero Host Cell System
Crucial role of CD11c+ dendritic cells
Max Planck Institute Magdeburg
 CD11c+ dendritic cells were separated by magnetic cell separation (MACS) 
and co-cultivated with TCR-HA transgenic T cells
 Dendritic cells are responsible for the differential T cell activation, 
presumably by differential recognition and/or uptake of the glycovariants 
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Adoptive transfer of transgenic T cells
TCR-HA Tg mouse
Isolation of 
spleen cells
Staining with 
cell dye e670
T cell separation 
by MACS
Max Planck Institute Magdeburg
Balb/c wt mouse
Analysis of proliferation 
and cell activation (FACS, 
ELISpot) 
Immunization with 
influenza glycovariants
1 day4 days
Adoptive T cell 
transfer
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In vivo T cell activation and proliferation
Max Planck Institute Magdeburg
 Increased IL-2 production upon immunization with Vero cell-derived glycovariant 
=> observed effects might also be relevant in vivo
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